Role of resveratrol-induced CD11b + Gr-1 + myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3 + T cells and amelioration of chronic colitis in IL-10 -/- mice

Brain, Behavior, and Immunity

Volumn 26, Issue 1, 2012, Pages 72-82

  Singh, Udai P ^a   Singh, Narendra P ^a   Singh, Balwan ^b   Hofseth, Lorne J ^c   Taub, Dennis D ^d   Price, Robert L ^a   Nagarkatti, Mitzi ^a   Nagarkatti, Prakash S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CD11b + and Gr 1 +; Colitis; CXCR3; Inflammation; MDSCs; Resveratrol

Indexed keywords

ANTIINFLAMMATORY AGENT; CD11B ANTIGEN; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; RANTES; RESVERATROL; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; COCULTURE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; IMMUNOREGULATION; LAMINA PROPRIA; LYMPHOCYTE COUNT; MESENTERY LYMPH NODE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; SPLEEN; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 CELL;

ANIMALS; ANTIGENS, CD11B; CELL PROLIFERATION; CELL SEPARATION; CHRONIC DISEASE; COLITIS; CYTOKINES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FLOW CYTOMETRY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN-10; MICE; MICE, KNOCKOUT; MUCOUS MEMBRANE; MYELOID CELLS; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR3; SERUM AMYLOID A PROTEIN; SPLEEN; STILBENES; T-LYMPHOCYTES; WEIGHT LOSS;

EID: 81355147515     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.07.236     Document Type: Article

References (52)

1. Birrell M.A., McCluskie K., Wong S., Donnelly L.E., Barnes P.J., Belvisi M.G. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J 2005, 19:840-841.
2. Bonecchi R., Bianchi G., Bordignon P.P., D'ambrosio D., Lang R., Borsatti A., Sozzani S., Allavena P., Gray P.A., Mantovani A., Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 1998, 187:129-134.
3. Casini-Raggi V., Kam L., Chong Y.J., Fiocchi C., Pizarro T.T., Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 1995, 154:2434-2440.
4. Cui X., Jin Y., Hofseth A.B., Pena E., Habiger J., Chumanevich A., Poudyal D., Nagarkatti M., Nagarkatti P.S., Singh U.P., Hofseth L.J. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev. Res. (Phila.) 2010, 3:549-559.
5. Davidson N.J., Leach M.W., Fort M.M., Thompson-Snipes L., Kuhn R., Muller W., Berg D.J., Rennick D.M. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J. Exp. Med. 1996, 184:241-251.
6. De Beer F.C., Mallya R.K., Fagan E.A., Lanham J.G., Hughes G.R., Pepys M.B. Serum amyloid - A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982, 2:231-234.
7. de la Lastra C.A., Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res. 2005, 49:405-430.
8. De Santo C., Salio M., Masri S.H., Lee L.Y., Dong T., Speak A.O., Porubsky S., Booth S., Veerapen N., Besra G.S., Grone H.J., Platt F.M., Zambon M., Cerundolo V. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Invest. 2008, 118:4036-4048.
9. Elmali N., Esenkaya I., Harma A., Ertem K., Turkoz Y., Mizrak B. Effect of resveratrol in experimental osteoarthritis in rabbits. Inflamm. Res. 2005, 54:158-162.
10. Farber J.M. Mig and IP-10 - CXC chemokines that target lymphocytes. J. Leukoc. Biol. 1997, 61:246-257.
11. Fukuzawa H., Sawada M., Kayahara T., Morita-Fujisawa Y., Suzuki K., Seno H., Takaishi S., Chiba T. Identification of GM-CSF in Paneth cells using single-cell RT-PCR. Biochem. Biophys. Res. Commun. 2003, 312:897-902.
12. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
13. Gholam P.M., Flancbaum L., Machan J.T., Charney D.A., Kotler D.P. Nonalcoholic fatty liver disease in severely obese subjects. Am. J. Gastroenterol. 2007, 102:399-408.
14. Haile L.A., von Wasielewski R., Gamrekelashvili J., Kruger C., Bachmann O., Westendorf A.M., Buer J., Liblau R., Manns M.P., Korangy F., Greten T.F. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 2008, 135:871-881. (e871-e875).
15. Hanson E.M., Clements V.K., Sinha P., Ilkovitch D., Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate l-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 2009, 183:937-944.
16. Head K., Jurenka J.S. Inflammatory bowel disease. Part II: Crohn's disease - pathophysiology and conventional and alternative treatment options. Altern. Med. Rev. 2004, 9:360-401.
17. Hegde V.L., Nagarkatti M., Nagarkatti P.S. Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur. J. Immunol. 2010, 40:3358-3371.
18. Hegde V.L., Nagarkatti P.S., Nagarkatti M. Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of trpv1 receptors by cannabidiol. PLoS ONE 2011, 6:e18281.
19. Hommes D.W., Meenan J., Dijkhuizen S., Ten Kate F.J., Tytgat G.N., Van Deventer S.J. Efficacy of recombinant granulocyte colony-stimulating factor (rhG-CSF) in experimental colitis. Clin. Exp. Immunol. 1996, 106:529-533.
20. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
21. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
22. Hyun J.G., Lee G., Brown J.B., Grimm G.R., Tang Y., Mittal N., Dirisina R., Zhang Z., Fryer J.P., Weinstock J.V., Luster A.D., Barrett T.A. Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm. Bowel Dis. 2005, 11:799-805.
23. Jiang J., Wang Z., Li Z., Zhang J., Wang C., Xu X., Qin Z. Early exposure of high-dose interleukin-4 to tumor stroma reverses myeloid cell-mediated T-cell suppression. Gene Ther. 2010, 17(8):991-999.
24. Kamada N., Hisamatsu T., Honda H., Kobayashi T., Chinen H., Takayama T., Kitazume M.T., Okamoto S., Koganei K., Sugita A., Kanai T., Hibi T. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm. Bowel Dis. 2010, 16:568-575.
25. Kim S.W., Choi S.C., Choi E.Y., Kim K.S., Oh J.M., Lee H.J., Oh H.M., Kim S., Oh B.S., Kimm K.C., Lee M.H., Seo G.S., Kim T.H., Oh H.C., Woo W.H., Kim Y.S., Pae H.O., Park D.S., Chung H.T., Jun C.D. Catalposide, a compound isolated from catalpa ovata, attenuates induction of intestinal epithelial proinflammatory gene expression and reduces the severity of trinitrobenzene sulfonic acid-induced colitis in mice. Inflamm. Bowel Dis. 2004, 10:564-572.
26. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003, 63:4441-4449.
27. Lillard J.W., Boyaka P.N., Taub D.D., McGhee J.R. RANTES potentiates antigen-specific mucosal immune responses. J. Immunol. 2001, 166:162-169.
28. Loetscher P., Pellegrino A., Gong J.H., Mattioli I., Loetscher M., Bardi G., Baggiolini M., Clark-Lewis I. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J. Biol. Chem. 2001, 276:2986-2991.
29. Martin A.R., Villegas I., La Casa C., de la Lastra C.A. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem. Pharmacol. 2004, 67:1399-1410.
30. Martin A.R., Villegas I., Sanchez-Hidalgo M., de la Lastra C.A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol. 2006, 147:873-885.
31. Maynard C.L., Weaver C.T. Intestinal effector T cells in health and disease. Immunity 2009, 31:389-400.
32. Mouser J.F., Hyams J.S. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clinical Therapeutics 1999, 21:932-942. (discussion 931).
33. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 2010, 59(10):1593-1600.
34. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506.
35. Pan P.Y., Wang G.X., Yin B., Ozao J., Ku T., Divino C.M., Chen S.H. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008, 111:219-228.
36. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 2010, 22:238-244.
37. Podolsky D.K. The current future understanding of inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 2002, 16:933-943.
38. Powrie F., Leach M.W., Mauze S., Menon S., Caddle L.B., Coffman R.L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994, 1:553-562.
39. Rodriguez P.C., Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 2008, 222:180-191.
40. Scheerens H., Hessel E., de Waal-Malefyt R., Leach M.W., Rennick D. Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10-/- mice and Rag-2-/- mice reconstituted with CD4+CD45RBhigh T cells. Eur. J. Immunol. 2001, 31:1465-1474.
41. Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16:53-65.
42. Serafini P., Mgebroff S., Noonan K., Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008, 68:5439-5449.
43. Singh U.P., Singh S., Taub D.D., Lillard J.W. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10(-/-) mice. J. Immunol. 2003, 171:1401-1406.
44. Singh U.P., Singh S., Weaver C.T., Iqbal N., McGhee J.R., Lillard J.W. IFN-g-inducible chemokines enhance adaptive immunity and colitis. J. Interferon Cytokine Res. 2003, 23:2000.
45. Singh N.P., Hegde V.L., Hofseth L.J., Nagarkatti M., Nagarkatti P. Resveratrol (trans-3, 5, 4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol. Pharmacol. 2007, 72:1508-1521.
46. Singh U.P., Singh S., Singh R., Karls R.K., Quinn F.D., Potter M.E., Lillard J.W. Influence of Mycobacterium avium subsp. paratuberculosis on colitis development and specific immune responses during disease. Infect. Immun. 2007, 75:3722-3728.
47. Singh U.P., Singh N.P., Singh B., Hofseth L.J., Price R.L., Nagarkatti M., Nagarkatti P.S. Resveratrol (trans-3, 5, 4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J. Pharmacol. Exp. Ther. 2010, 332:829-839.
48. Singh N.P., Singh U.P., Hegde V.L., Guan H., Hofseth L., Nagarkatti M., Nagarkatti P.S. Resveratrol (trans-3, 5, 4'-trihydroxystilbene) suppresses EL4 tumor growth by induction of apoptosis involving reciprocal regulation of SIRT1 and NF-kappaB. Mol. Nutr. Food Res. 2011, 55:1-12.
49. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 2002, 20:495-549.
50. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 2007, 117:514-521.
51. Wu S.L., Yu L., Jiao X.Y., Meng K.W., Pan C.E. The suppressive effect of resveratrol on protein kinase C theta in peripheral blood T lymphocytes in a rat liver transplantation model. Transplant. Proc. 2006, 38:3052-3054.
52. Yuan Y.H., ten Hove T., The F.O., Slors J.F., van Deventer S.J., te Velde A.A. Chemokine receptor CXCR3 expression in inflammatory bowel disease. Inflamm. Bowel Dis. 2001, 7:281-286.